Literature DB >> 25665007

Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss.

Heng Xu1, Giles W Robinson2, Jie Huang3, Joshua Yew-Suang Lim4, Hui Zhang5, Johnnie K Bass6, Alberto Broniscer2, Murali Chintagumpala7, Ute Bartels8, Sri Gururangan9, Tim Hassall10, Michael Fisher11, Richard Cohn12, Tetsuji Yamashita13, Tal Teitz13, Jian Zuo13, Arzu Onar-Thomas3, Amar Gajjar2, Clinton F Stewart5, Jun J Yang5.   

Abstract

Taking a genome-wide association study approach, we identified inherited genetic variations in ACYP2 associated with cisplatin-related ototoxicity (rs1872328: P = 3.9 × 10(-8), hazard ratio = 4.5) in 238 children with newly diagnosed brain tumors, with independent replication in 68 similarly treated children. The ACYP2 risk variant strongly predisposed these patients to precipitous hearing loss and was related to ototoxicity severity. These results point to new biology underlying the ototoxic effects of platinum agents.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25665007      PMCID： PMC4358157          DOI： 10.1038/ng.3217

Source DB:  PubMed          Journal:  Nat Genet        ISSN： 1061-4036            Impact factor:   38.330


  35 in total

1.  A permutation test for inference in logistic regression with small- and moderate-sized data sets.

Authors:  Douglas M Potter
Journal:  Stat Med       Date:  2005-03-15       Impact factor: 2.373

2.  Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose.

Authors:  Y Li; R B Womer; J H Silber
Journal:  Eur J Cancer       Date:  2004-11       Impact factor: 9.162

3.  Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors.

Authors:  Jan Oldenburg; Sigrid M Kraggerud; Milada Cvancarova; Ragnhild A Lothe; Sophie D Fossa
Journal:  J Clin Oncol       Date:  2007-01-16       Impact factor: 44.544

4.  Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial.

Authors:  Amar Gajjar; Murali Chintagumpala; David Ashley; Stewart Kellie; Larry E Kun; Thomas E Merchant; Shaio Woo; Greg Wheeler; Valerie Ahern; Matthew J Krasin; Maryam Fouladi; Alberto Broniscer; Robert Krance; Gregory A Hale; Clinton F Stewart; Robert Dauser; Robert A Sanford; Christine Fuller; Ching Lau; James M Boyett; Dana Wallace; Richard J Gilbertson
Journal:  Lancet Oncol       Date:  2006-10       Impact factor: 41.316

5.  Characterization of transcriptomes of cochlear inner and outer hair cells.

Authors:  Huizhan Liu; Jason L Pecka; Qian Zhang; Garrett A Soukup; Kirk W Beisel; David Z Z He
Journal:  J Neurosci       Date:  2014-08-13       Impact factor: 6.167

6.  Evaluation of pharmacogenetic markers to predict the risk of Cisplatin-induced ototoxicity.

Authors:  C Lanvers-Kaminsky; I Malath; D Deuster; G Ciarimboli; J Boos; A G Am Zehnhoff-Dinnesen
Journal:  Clin Pharmacol Ther       Date:  2014-03-18       Impact factor: 6.875

7.  Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma.

Authors:  James G Gurney; Johnnie K Bass; Arzu Onar-Thomas; Jie Huang; Murali Chintagumpala; Eric Bouffet; Tim Hassall; Sridharan Gururangan; John A Heath; Stewart Kellie; Richard Cohn; Michael J Fisher; Atmaram Pai Panandiker; Thomas E Merchant; Ashok Srinivasan; Cynthia Wetmore; Ibrahim Qaddoumi; Clinton F Stewart; Gregory T Armstrong; Alberto Broniscer; Amar Gajjar
Journal:  Neuro Oncol       Date:  2014-01-10       Impact factor: 12.300

8.  Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma.

Authors:  Brian H Kushner; Amy Budnick; Kim Kramer; Shakeel Modak; Nai-Kong V Cheung
Journal:  Cancer       Date:  2006-07-15       Impact factor: 6.860

Review 9.  Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics.

Authors:  Lois B Travis; Sophie D Fossa; Howard D Sesso; Robert D Frisina; David N Herrmann; Clair J Beard; Darren R Feldman; Lance C Pagliaro; Robert C Miller; David J Vaughn; Lawrence H Einhorn; Nancy J Cox; M Eileen Dolan
Journal:  J Natl Cancer Inst       Date:  2014-03-12       Impact factor: 13.506

10.  Population structure and eigenanalysis.

Authors:  Nick Patterson; Alkes L Price; David Reich
Journal:  PLoS Genet       Date:  2006-12       Impact factor: 5.917
View more
  36 in total

Review 1.  The clinical importance of medulloblastoma extent of resection: a systematic review.

Authors:  Eric M Thompson; Alexa Bramall; James E Herndon; Michael D Taylor; Vijay Ramaswamy
Journal:  J Neurooncol       Date:  2018-05-23       Impact factor: 4.130

Review 2.  Genome-Wide Association Studies of Chemotherapeutic Toxicities: Genomics of Inequality.

Authors:  Brandon Mapes; Omar El Charif; Shereen Al-Sawwaf; M Eileen Dolan
Journal:  Clin Cancer Res       Date:  2017-04-25       Impact factor: 12.531

Review 3.  Platinum-induced ototoxicity: a review of prevailing ototoxicity criteria.

Authors:  Sofia Waissbluth; Emilia Peleva; Sam J Daniel
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-05-31       Impact factor: 2.503

Review 4.  Personalized medicine: Genetic risk prediction of drug response.

Authors:  Ge Zhang; Daniel W Nebert
Journal:  Pharmacol Ther       Date:  2017-02-14       Impact factor: 12.310

Review 5.  An integrated view of cisplatin-induced nephrotoxicity and ototoxicity.

Authors:  Takatoshi Karasawa; Peter S Steyger
Journal:  Toxicol Lett       Date:  2015-06-20       Impact factor: 4.372

6.  Variants in WFS1 and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity.

Authors:  Heather E Wheeler; Eric R Gamazon; Robert D Frisina; Carlos Perez-Cervantes; Omar El Charif; Brandon Mapes; Sophie D Fossa; Darren R Feldman; Robert J Hamilton; David J Vaughn; Clair J Beard; Chunkit Fung; Christian Kollmannsberger; Jeri Kim; Taisei Mushiroda; Michiaki Kubo; Shirin Ardeshir-Rouhani-Fard; Lawrence H Einhorn; Nancy J Cox; M Eileen Dolan; Lois B Travis
Journal:  Clin Cancer Res       Date:  2016-12-30       Impact factor: 12.531

Review 7.  Diagnostic and therapeutic applications of genomic medicine in progressive, late-onset, nonsyndromic sensorineural hearing loss.

Authors:  Joaquin E Jimenez; Aida Nourbakhsh; Brett Colbert; Rahul Mittal; Denise Yan; Carlos L Green; Eric Nisenbaum; George Liu; Nicole Bencie; Jason Rudman; Susan H Blanton; Xue Zhong Liu
Journal:  Gene       Date:  2020-04-15       Impact factor: 3.688

8.  Promoter region variation in NFE2L2 influences susceptibility to ototoxicity in patients exposed to high cumulative doses of cisplatin.

Authors:  T F Spracklen; A A Vorster; L Ramma; S Dalvie; R S Ramesar
Journal:  Pharmacogenomics J       Date:  2016-07-26       Impact factor: 3.550

9.  Association of ACYP2 and TSPYL6 Genetic Polymorphisms with Risk of Ischemic Stroke in Han Chinese Population.

Authors:  Yiqian Liang; Rui Zhang; Shuo Zhang; Guofa Ji; Puyu Shi; Tian Yang; Feng Liu; Jing Feng; Chunqi Li; Dangshe Guo; Mingwei Chen
Journal:  Mol Neurobiol       Date:  2016-09-29       Impact factor: 5.590

Review 10.  Genetic and Modifiable Risk Factors Contributing to Cisplatin-induced Toxicities.

Authors:  Matthew R Trendowski; Omar El Charif; Paul C Dinh; Lois B Travis; M Eileen Dolan
Journal:  Clin Cancer Res       Date:  2018-10-10       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.